½ÃÀ庸°í¼­
»óǰÄÚµå
1679378

Àڱ⠳úÆÄ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Magnetoencephalography Market Size, Share & Trends Analysis Report By Application (Clinical, Research), By End Use (Hospitals, Imaging Centers), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àڱ⠳úÆÄ(MEG) ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ Àڱ⠳úÆÄ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 4¾ï 3,260¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025-2030³âÀÇ CAGRÀº 5.9%¸¦ º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ½ÅÁ¦Ç° Ãâ½Ã ºóµµÀÇ Áõ°¡¿Í °£Áú, ³úÁ¹Áß°ú °°Àº ½Å°æ°è ÁúȯÀÇ ¹ßº´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä µ¿ÀÎÀÔ´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ½Å°æ ÅðÇ༺ Áúȯ¿¡ ´õ Ãë¾àÇϱ⠶§¹®¿¡ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°èº¸°Ç±â±¸¿¡ µû¸£¸é ½Å°æ°è ÁúȯÀº Àü ¼¼°è »ç¸ÁÀÇ 12%¸¦ Â÷ÁöÇÏ´Â ÁÖ¿ä »ç¸Á ¿øÀÎÀÔ´Ï´Ù.

MEG ±â¼úÀº ³ú¿¡¼­ »ý¼ºµÇ´Â ¾àÇÑ ÀÚ±âÀåÀ» °¨ÁöÇÏ¿© ³ú ±â´ÉÀ» Á¤·®È­ÇÏ°í ³ú Ȱµ¿À» ¸ÅÇÎÇÏ´Â µ¥ »ç¿ëÇÕ´Ï´Ù. ÀÓ»ó ȯ°æ¿¡¼­ MEG´Â ¿©·¯ °¡Áö °íÀ¯ÇÑ ÀÀ¿ë ºÐ¾ß¸¦ Á¦°øÇÕ´Ï´Ù. ±â·ÏÀÇ ¼öµ¿Àû Ư¼ºÀ¸·Î ÀÎÇØ ¾ÈÀüÇϰí Á¶¿ëÇÑ ºÐÀ§±â¿¡¼­ ½ºÄµÀ» ¼öÇàÇÒ ¼ö ÀÖÀ¸¸ç, ȯÀÚÀÇ µ¿¹ÝÀÚ°¡ Â÷ÆóµÈ ¿µ¿ª ³»¿¡ ÀÖÀ» ¼öµµ ÀÖ½À´Ï´Ù.

ÀüµÎºÎ ½Ã½ºÅÛÀÇ µµÀÔ°ú ÄÄÇ»ÅÍ ±â¼úÀÇ ¹ßÀü µî ±â¼ú ¹ßÀüÀÌ ½ÃÀå È®´ë¿¡ ±â¿©ÇÒ °ÍÀ¸·Î º¸ÀÌ´Â MEG´Â Áö³­ 20³â µ¿¾È Å©°Ô ¹ßÀüÇØ ¿Ô½À´Ï´Ù. Á¤¹ÐÇÏ°í ³ôÀº ¼öÁØÀÇ ±¹¼ÒÈ­°¡ ÇÊ¿äÇÒ ¶§¸¶´Ù MEG´Â ÀÌÁ¦ ¼±ÅõǴ ¿µ»ó ÃÔ¿µ ¹æ½ÄÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÚ±â³úÀÚµµ(MEG)´Â ¿¬±¸ÀÚµéÀÌ ´ë±Ô¸ð ³ú Ȱµ¿ÀÇ ¿¬°á°ú ¿ªÇÐÀ» ¿¬±¸ÇÏ´Â µ¥ »ç¿ëÇÏ´Â ±ÍÁßÇÑ µµ±¸ÀÔ´Ï´Ù.

½ÃÀåÀÇ Àú¸íÇÑ °æÀïÀÚµéÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí Á¦Á¶ ¿ª·®À» °­È­Çϱâ À§ÇØ Áß¼Ò±â¾÷À» ÀμöÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ³ëÆÃ¾ö ´ëÇÐÀº ÄËÆ®ÀÇ Magnetic Shields Limited(MSL)¿Í Á¦ÈÞÇÏ¿© ¼¼°è ÃÖ÷´Ü ±â´ÉÀû ¿þ¾î·¯ºí ³ú ½ºÄ³³Ê¸¦ ½ÃÀå¿¡ ³»º¸³»´Â ½ºÇɾƿô ½Åȸ»çÀÎ Buse Magnetics Limited¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ ½ºÄ³³Ê´Â ½ºÄµÀ» ¹Þ´Â µ¿¾È »ç¶÷µéÀÌ ÀÚÀ¯·Ó°Ô ¿òÁ÷ÀÏ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

Àڱ⠳úÆÄ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ¿ëµµº°·Î´Â ÀÓ»ó ºÎ¹®Àº 2024³â¿¡ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È 6.1%ÀÇ °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÀÓ»ó ºÎ¹®Àº Ä¡¸Å, ÀÚÆóÁõ, Á¤½Å ºÐ¿­Áõ, ´Ù¹ß¼º °æÈ­Áõ, ³úÁ¹Áß, °£Áú ¹× ±âŸ·Î ¼¼ºÐÈ­µÇ¸ç, °£Áú ÇÏÀ§ ºÎ¹®Àº Àü ¼¼°èÀûÀ¸·Î À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®Àº °³¹ß µµ»ó±¹ÀÇ º´¿ø ¼ö°¡ Áõ°¡Çϰí ÀÇ·á ¼­ºñ½º Á¦°ø ¾÷ü °£ÀÇ °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó 2024³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • À̹Ì¡ ¼¾ÅÍ ºÎ¹®Àº ȯÀÚ¿Í º¸Çè»ç¿¡ ´ëÇÑ ÆíÀǼº, ±ÙÁ¢¼º ¹× ³·Àº ºñ¿ëÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå·üÀ» °æÇèÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â 2024³â 33.9%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î Àڱ⠳úÆÄ °Ë»ç ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÁÖ¿ä Á¦Á¶¾÷üÀÇ Á¸Àç, R&D ÅõÀÚ Áõ°¡, Á¤ºÎ ÀÚ±Ý ¹× Áö¿øÀÇ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Àڱ⠳úÆÄ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅëÀÇ Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • Àڱ⠳úÆÄ ½ÃÀå ºÐ¼® Åø
    • »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå Àڱ⠳úÆÄ ½ÃÀå : ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Àڱ⠳úÆÄ, ¿ëµµ ½ÃÀå º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Àڱ⠳úÆÄ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°(2018-2030³â)
  • ÀÓ»ó
    • Ä¡¸Å
    • ÀÚÆóÁõ
    • Á¤½Å ºÐ¿­Áõ
    • ´Ù¹ß¼º °æÈ­Áõ
    • ³úÁ¹Áß
    • °£Áú
    • ±âŸ
  • ¿¬±¸

Á¦5Àå Àڱ⠳úÆÄ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Àڱ⠳úÆÄ ½ÃÀå ÃÖÁ¾ ¿ëµµ ½ÃÀå º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Àڱ⠳úÆÄ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • º´¿ø
  • À̹Ì¡ ¼¾ÅÍ
  • Çмú ¹× ¿¬±¸±â°ü

Á¦6Àå Àڱ⠳úÆÄ ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â, 2030³â)
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°èÀÇ Áö¿ª ½ÃÀå ÇöȲ
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ±ÔÁ¦ Ʋ ¹× »óȯ ±¸Á¶
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±ÔÁ¦ Ʋ ¹× »óȯ ±¸Á¶
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±ÔÁ¦ Ʋ ¹× »óȯ ±¸Á¶
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ±ÔÁ¦ Ʋ ¹× »óȯ ±¸Á¶
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷ ¹× °æÀï»ç ºÐ·ù
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ±â¾÷ Æ÷Áö¼Ç ºÐ¼®
  • ±â¾÷ºÐ·ù(½ÅÈï±â¾÷, À̳뺣ÀÌÅÍ, ¸®´õ)
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Compumedics Limited
    • MEGIN
    • Ricoh
    • CTF MEG NEURO INNOVATIONS, INC.
    • FieldLine Inc.
    • Cerca Magnetics Limited
HBR 25.04.11

Magnetoencephalography Market Growth & Trends:

The global magnetoencephalography market size is estimated to reach USD 432.6 million by 2030, expanding at a CAGR of 5.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing frequency of new product launches and the rise in the incidence of neurological disorders such as epilepsy, and stroke are key drivers to market growth. In addition, the growing geriatric population is also expected to drive market growth since they are more prone to neurodegenerative diseases. According to the World Health Organization, neurological disorders are a leading cause of death, accounting for 12% of all deaths worldwide.

MEG technologies detect the weak magnetic fields created in the brain and use them to quantify brain functionality and map brain activity. In a clinical setting, MEG provides a number of inherent applications. Scans can be performed in a safe and silent atmosphere due to the passive nature of the recordings, which even allows a patient's companion to be present within the shielded area.

Technological developments are likely to contribute to market expansion, such as the introduction of whole-head systems and developments in computer technology, MEG has evolved significantly in the last two decades. Whenever a precise and high degree of localization is required, MEG is now the imaging modality of choice. Furthermore, magnetoencephalography (MEG), is an invaluable tool that is used by researchers to study the connections and dynamics of large-scale brain activity.

The market's prominent competitors are acquiring medium and small-sized businesses in order to expand their product portfolio and enhance their manufacturing capacity. For instance, the University of Nottingham has partnered with Magnetic Shields Limited (MSL) of Kent to develop Cerca Magnetics Limited, a new spin-out company that will deliver the world's most advanced functional wearable brain scanner to market. It is designed to let people move around freely while being scanned.

Magnetoencephalography Market Report Highlights:

  • Based on application, the clinical segment accounted for the largest revenue share in 2024 and is further expected to grow at the fastest CAGR of 6.1% over the forecast period.
  • The clinical segment is further sub-segmented into dementia, autism, schizophrenia, multiple sclerosis, stroke, epilepsy, and others, in which the epilepsy sub-segment held the largest market share owing to its increasing prevalence worldwide
  • In terms of end use, the hospital segment held the largest share in 2024, owing to the increasing number of hospitals in developing countries and growing competition among healthcare service providers
  • The imaging center segment is expected to experience the fastest growth rate during the forecast period due to its convenience, proximity, and lower costs to patients and insurers
  • North America dominated the magnetoencephalography market with the largest revenue share of 33.9% in 2024. The presence of key manufacturers in the region, increase in R&D investments, and rise in government funding & initiatives are expected to boost market growth over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Magnetoencephalography Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increase in prevalence of neurological disorders
      • 3.2.1.2. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of MEG
      • 3.2.2.2. Presence of alternative diagnostic devices
  • 3.3. Magnetoencephalography Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Magnetoencephalography Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Magnetoencephalography Application Market Movement Analysis
  • 4.3. Global Magnetoencephalography Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Clinical
    • 4.4.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Dementia
      • 4.4.2.1. Dementia diagnosis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Autism
      • 4.4.3.1. Autism market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Schizophrenia
      • 4.4.4.1. Schizophrenia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Multiple Sclerosis
      • 4.4.5.1. Multiple sclerosis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Stroke
      • 4.4.6.1. Stroke market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Epilepsy
      • 4.4.7.1. Epilepsy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.8. Others
      • 4.4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Research
    • 4.5.1. Research market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Magnetoencephalography Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Magnetoencephalography End Use Market Movement Analysis
  • 5.3. Global Magnetoencephalography Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Imaging Centers
    • 5.5.1. Imaging centers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Academic and Research Institutes
    • 5.6.1. Academic and research institutes market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Magnetoencephalography Market: Regional Estimates & Trend Analysis By Application, End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Competitive scenario
      • 6.5.1.3. Regulatory framework/ reimbursement structure
      • 6.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework/ reimbursement structure
      • 6.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework/ reimbursement structure
      • 6.5.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Regulatory framework/ reimbursement structure
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework/ reimbursement structure
      • 6.6.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework/ reimbursement structure
      • 6.6.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Competitive scenario
      • 6.6.4.3. Regulatory framework/ reimbursement structure
      • 6.6.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Competitive scenario
      • 6.6.5.3. Regulatory framework/ reimbursement structure
      • 6.6.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Competitive scenario
      • 6.6.6.3. Regulatory framework/ reimbursement structure
      • 6.6.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Competitive scenario
      • 6.6.7.3. Regulatory framework/ reimbursement structure
      • 6.6.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Competitive scenario
      • 6.6.8.3. Regulatory framework/ reimbursement structure
      • 6.6.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Competitive scenario
      • 6.6.9.3. Regulatory framework/ reimbursement structure
      • 6.6.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Regulatory framework/ reimbursement structure
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework/ reimbursement structure
      • 6.7.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework/ reimbursement structure
      • 6.7.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework/ reimbursement structure
      • 6.7.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework/ reimbursement structure
      • 6.7.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Competitive scenario
      • 6.7.6.3. Regulatory framework/ reimbursement structure
      • 6.7.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Competitive scenario
      • 6.7.7.3. Regulatory framework/ reimbursement structure
      • 6.7.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Regulatory framework/ reimbursement structure
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Competitive scenario
      • 6.8.2.3. Regulatory framework/ reimbursement structure
      • 6.8.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Competitive scenario
      • 6.8.3.3. Regulatory framework/ reimbursement structure
      • 6.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. Regulatory framework/ reimbursement structure
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Competitive scenario
      • 6.9.2.3. Regulatory framework/ reimbursement structure
      • 6.9.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Competitive scenario
      • 6.9.3.3. Regulatory framework/ reimbursement structure
      • 6.9.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Competitive scenario
      • 6.9.4.3. Regulatory framework/ reimbursement structure
      • 6.9.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Competitive scenario
      • 6.9.5.3. Regulatory framework/ reimbursement structure
      • 6.9.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share analysis, 2024
  • 7.4. Company Position Analysis
  • 7.5. Company Categorization (Emerging Players, Innovators and Leaders
  • 7.6. Company Profiles
    • 7.6.1. Compumedics Limited
      • 7.6.1.1. Company overview
      • 7.6.1.2. Financial performance
      • 7.6.1.3. Product benchmarking
      • 7.6.1.4. Strategic initiatives
    • 7.6.2. MEGIN
      • 7.6.2.1. Company overview
      • 7.6.2.2. Financial performance
      • 7.6.2.3. Product benchmarking
      • 7.6.2.4. Strategic initiatives
    • 7.6.3. Ricoh
      • 7.6.3.1. Company overview
      • 7.6.3.2. Financial performance
      • 7.6.3.3. Product benchmarking
      • 7.6.3.4. Strategic initiatives
    • 7.6.4. CTF MEG NEURO INNOVATIONS, INC.
      • 7.6.4.1. Company overview
      • 7.6.4.2. Financial performance
      • 7.6.4.3. Product benchmarking
      • 7.6.4.4. Strategic initiatives
    • 7.6.5. FieldLine Inc.
      • 7.6.5.1. Company overview
      • 7.6.5.2. Financial performance
      • 7.6.5.3. Product benchmarking
      • 7.6.5.4. Strategic initiatives
    • 7.6.6. Cerca Magnetics Limited
      • 7.6.6.1. Company overview
      • 7.6.6.2. Financial performance
      • 7.6.6.3. Product benchmarking
      • 7.6.6.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦